Evaluation of rational use of intravenous iron in patients with iron deficient anemia and abnormal uterine bleeding in gynaecology
10.12173/j.issn.1008-049X.202312198
- VernacularTitle:静脉铁剂在妇科异常子宫出血缺铁性贫血患者中的合理应用评价
- Author:
Jing XU
1
;
Hua ZHANG
;
Fan LI
;
Mingwei LI
;
Xiaojuan WANG
Author Information
1. 安徽理工大学第一附属医院(淮南市第一人民医院)药学部(安徽淮南 232007)
- Keywords:
Drug utilization evaluation standard;
Analytic hierarchy process;
Abnormal uterine bleeding;
Iron deficiency anemia;
Iron sucrose injection;
Evaluation standard
- From:
China Pharmacist
2024;27(2):272-278
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the application of intravenous iron in patients with abnormal uterine bleeding(AUD)and iron deficiency anemia(IDA)in gynecology,to establish the drug utilization evaluation(DUE)standard,and to comprehensively evaluate the rationality of the clinical application of intravenous iron by analytic hierarchy process(AHP),so as to provide reference for the rational use of intravenous iron in clinical practice.Methods The medical records of patients with AUD and IDA from January to December 2022 in the First Affiliated Hospital of Anhui University of Science and Technology were collected,and the special rationality of the drug was evaluated from the aspects of indications,route and frequency of administration,daily dosage,solvent,combination medication,and contraindications of iron sucrose injection,and the DUE standard of the drug was formulated.AHP was used to analyze and evaluate 113 archived cases of intravenous iron in gynecology from January to December 2022.Results A total of 113 patients were treated with iron sucrose injection,and the indications,route of administration,solvent,contraindications,and allergic reactions were reasonable.The main unreasonableness was that the frequency of administration was inappropriate,the daily dose was inappropriate,the combination was not appropriate,the total iron supplement was not up to standard,and there was no continuous drug monitoring after medication.The case scores 90～100,70～<90 and 60～<70 were 6(5.31%),106(93.81%)and 1(0.88%),respectively.Conclusion Patients with AUD and IDA should pay attention to the dosage,total amount of iron supplementation,combined application of drugs and continuous medication monitoring after intravenous iron supplementation,so as to improve the rationality of their use.
